Sandbox Reserved 825: Difference between revisions
From Proteopedia
Jump to navigationJump to search
| Line 30: | Line 30: | ||
== '''Structure of FRB''' == | == '''Structure of FRB''' == | ||
[[Image:FRB Phosphatidic Acid.png|upright=1.25|right|thumb| Fig.2 A representative view of phosphatidic acid docked into its binding site on the FRB domain.]] | [[Image:FRB Phosphatidic Acid.png|upright=1.25|right|thumb| Fig.2 A representative view of phosphatidic acid docked into its binding site on the FRB domain.]] | ||
| Line 47: | Line 48: | ||
{{clear}} | {{clear}} | ||
Other molecules like the novel class inhibitor '''HTS-1''' (4-[6-{[(1S,2R)-2-(benzyloxy)cyclopentyl]acety}-4-(2-thienyl)pyridin-2-yl]-4-oxobutanoic acid) | Other molecules like the novel class inhibitor '''HTS-1''' (4-[6-{[(1S,2R)-2-(benzyloxy)cyclopentyl]acety}-4-(2-thienyl)pyridin-2-yl]-4-oxobutanoic acid) | ||
| Line 55: | Line 55: | ||
</ref> | </ref> | ||
[[Image:FRB HTS-1 Rapamycin.png|center|upright=2| thumb| Fig.3 A representative view of the mTOR inhibitor HTS-1 docked into its binding site on the FRB domain on the left. On the right, the location and conformation of rapamycin bound to the FRB domain in the ternary complex formed with FKBP12 is illustrated, with the domain shown in the same orientation as on the left.]] | |||
